LAKE FOREST, Ill., March 26, 2014 - Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today expressed its gratitude to Indiana Gov. Pence for his decision to sign SB 262, a law that creates a pathway for the substitution of interchangeable biologic drugs and helps pave the way for patient access to cost savings from biosimilar products.

The introduction of biosimilars in the United States will create opportunities for clinicians and patients to gain greater accessibility to effective and more affordable biologic drugs. One report predicts that U.S. biosimilars savings could be up to $250 billion over 10 years, helping to improve access to care at a lower cost.

"Working together, regulators and industry leaders can make this a reality, and put cost-savings from biosimilar drugs in the hands of patients and states, such as Indiana, that need these savings," said Nancy Martin M.D., PharmD, vice president, Global Clinical Development, Hospira, Inc.

The governor's signature on SB 262 will help educate patients and physicians on the safety of biosimilars and how they will reduce costs while also providing the opportunity for improved patient outcomes by increasing access to biologic therapies.  Hospira is preparing to bring biosimilars to patients in Indiana and across the United States as soon as mid-decade.

To learn more about Hospira's biosimilars, please visit http://www.hospira.com/healthcare_trends/biologics/index


distributed by